Overhead view of a doctor looking at his clipboard

Mesothelioma Research

Malignant pleural mesothelioma is a rare, aggressive lung cancer that develops in the pleura, a thin layer of tissue surrounding the lungs. Approximately 3,000 people are diagnosed each year in the United States.


Response rates to chemotherapy are generally less than 40%.

Five-year survival rates are less than 20%.

Aldeyra’s chaperome inhibitors, in combination with DNA-damaging agents, may have utility in the treatment of cancers such as mesothelioma and ovarian cancer. The chaperome inhibitor system is required for DNA repair, and chaperome inhibition in the setting of DNA damage could lead to cancer cell death.

Mesothelioma Clinical Trial Results

In an Investigator-Sponsored Clinical Trial in mesothelioma patients, the overall response rate to Aldeyra’s lead chaperome inhibitor ADX-1612 was 61%, relative to the historical standard of care response rates of 20% to 40%*. In seven patients, the reduction of tumor burden was greater than 50%. One patient remained progression-free after 37 months.

Change in patients treated with ADX-1612